Physician profile
Michael L Levin
NPI 1578524526
$54,813.83
in general payments reported to CMS, 2019-2025
29 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $395 · 2021: $19K · 2022: $15K · 2023: $16K · 2024: $2,727 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Honoraria: $4,400 · Food and Beverage: $2,302 · Consulting Fee: $1,760 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
| Honoraria | $4,400.00 |
| Food and Beverage | $2,302.23 |
| Consulting Fee | $1,760.00 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $44,568.94 | 2021-2025 | Lupkynis |
| Vifor Pharma, INC. | $6,744.69 | 2019-2024 | Veltassa |
| Ani Pharmaceuticals, INC. | $396.58 | 2023-2025 | Purified Cortrophin Gel |
| Amgen INC. | $390.19 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $312.04 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $272.53 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $245.33 | 2019-2025 | Jynarque, Voyxact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.10 | 2020-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $212.10 | 2019-2024 | Velphoro, Korsuva |
| Travere Therapeutics, INC. | $163.36 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $157.80 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $125.01 | 2019 | |
| Alexion Pharmaceuticals, INC. | $120.55 | 2019 | |
| Novo Nordisk INC | $90.62 | 2023-2025 | Rybelsus, Ozempic |
| Akebia Therapeutics INC | $88.09 | 2020-2024 | Vafseo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $86.44 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $85.96 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.70 | 2022-2023 | |
| Glaxosmithkline, LLC. | $76.47 | 2023-2025 | Benlysta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $72.51 | 2019-2023 | |
| Calliditas Therapeutics US INC. | $53.41 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $50.06 | 2019-2023 | Krystexxa |
| Abiomed | $35.50 | 2022 | |
| Ardelyx, INC. | $34.43 | 2025 | Ibsrela |
| Abbott Laboratories | $23.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.00 | 2025 | Livtencity |
| Daiichi Sankyo INC. | $22.14 | 2019 | |
| Lilly USA, LLC | $18.41 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $17.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.